Positron emission tomography (PET) was developed in the mid-1970, and its initial applications were for heart and brain imaging research. Nowadays, this technology is aimed mainly at staging or restaging tumours as it allows the assessment of biochemical processes that are either specific or associated with tumour biology. The full appreciation of PET potentials and limitations among general practitioners and internists cannot be considered achieved and the appropriate use of PET especially when coupled to X-ray computed tomography (CT) is still suboptimal. The majority of PET studies rely on the use of fluorodeoxyglucose labelled with fluorine-18 (FDG), which is a radiopharmaceutical specific for glucose transport and metabolism. PET with FDG is amenable for studying most type of tumours, including those of the head and neck, lung, oesophagus, colo-rectal, gastrointestinal stromal tumours, pancreas, some types of lymphomas and melanoma, whereas in some tumours, including those of the reproductive system, brain, breast and bones, there is a limited role for PET and there is no substantial role for FDG-PET for the bronchoalveolar, hepatocellular, urinary system, testicular, neuroendocrine, carcinoids and adrenal tumours, differentiated thyroid cancers, and several subtypes of malignant lymphoma. Thus, the limits of FDG have stimulated the use and development of other radiopharmaceuticals. These tracers represent the opportunity for expanding the use of PET to other areas in oncology in the near future.

Appropriate use of positron emission tomography with [18F]fluorodeoxyglucose for staging of oncology patients / L. Tagliabue, A. Del Sole. - In: EUROPEAN JOURNAL OF INTERNAL MEDICINE. - ISSN 0953-6205. - 25:1(2014 Jan), pp. 6-11. [10.1016/j.ejim.2013.06.012]

Appropriate use of positron emission tomography with [18F]fluorodeoxyglucose for staging of oncology patients

A. Del Sole
Ultimo
2014

Abstract

Positron emission tomography (PET) was developed in the mid-1970, and its initial applications were for heart and brain imaging research. Nowadays, this technology is aimed mainly at staging or restaging tumours as it allows the assessment of biochemical processes that are either specific or associated with tumour biology. The full appreciation of PET potentials and limitations among general practitioners and internists cannot be considered achieved and the appropriate use of PET especially when coupled to X-ray computed tomography (CT) is still suboptimal. The majority of PET studies rely on the use of fluorodeoxyglucose labelled with fluorine-18 (FDG), which is a radiopharmaceutical specific for glucose transport and metabolism. PET with FDG is amenable for studying most type of tumours, including those of the head and neck, lung, oesophagus, colo-rectal, gastrointestinal stromal tumours, pancreas, some types of lymphomas and melanoma, whereas in some tumours, including those of the reproductive system, brain, breast and bones, there is a limited role for PET and there is no substantial role for FDG-PET for the bronchoalveolar, hepatocellular, urinary system, testicular, neuroendocrine, carcinoids and adrenal tumours, differentiated thyroid cancers, and several subtypes of malignant lymphoma. Thus, the limits of FDG have stimulated the use and development of other radiopharmaceuticals. These tracers represent the opportunity for expanding the use of PET to other areas in oncology in the near future.
fluorodeoxyglucose; oncology; positron emission tomography; staging
Settore MED/36 - Diagnostica per Immagini e Radioterapia
Settore MED/06 - Oncologia Medica
gen-2014
Article (author)
File in questo prodotto:
File Dimensione Formato  
Tagliabue, Del Sole - 2013 - Appropriate use of positron emission tomography with (18)Ffluorodeoxyglucose for staging of oncology patien.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 306.99 kB
Formato Adobe PDF
306.99 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
1-s2.0-S0953620513001775-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 166.41 kB
Formato Adobe PDF
166.41 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/224736
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 25
  • ???jsp.display-item.citation.isi??? 23
social impact